Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA)

Hooper, Candace Y; Smith, W. L.

doi:10.2147/tcrm.s23247

Cited by 7 publications

(8 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the remaining studies, 421 studies were excluded after reading titles, abstracts or texts. Only 23 were retrieved full text for eligibility, of which 18 studies were excluded (Corey et al, 2007b , a , 2014 ; Stryjewski et al, 2008 , 2012 , 2013 ; Wilson et al, 2009 ; Barriere, 2010 , 2014 ; Rubinstein et al, 2011a , 2014 ; Hooper and Smith, 2012 ; Nannini et al, 2012 ; Barriere et al, 2014a , b ; Torres et al, 2014 ; Lacy et al, 2015 ). Thus, five studies comparing telavancin with control regimens were included in the meta-analysis (Stryjewski et al, 2005 , 2006 , 2008 , 2014 ; Rubinstein et al, 2011b ; Figure 1 ).…”

Section: Resultsmentioning

confidence: 99%

“…Some retrospective reviews and traditional reviews also studied the efficacy and safety of telavancin. However, without quality evaluation of including articles and statistical calculation of the data, the results were often influenced by subjective factors and biases (Dunbar et al, 2008 ; Chang et al, 2010 ; Hooper and Smith, 2012 ; Rubinstein et al, 2014 ; Nnedu and Pankey, 2015 ). Konstantinos A. Polyzos and colleagues did a meta-analysis to synthetically assess the efficacy and safety of telavancin, but it was limited to six published randomized controlled trials up to March 2012 (Polyzos et al, 2012 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Systematic Review and Meta-Analysis of the Efficacy and Safety of Telavancin for Treatment of Infectious Disease: Are We Clearer?

Chuan

Zhang

et al. 2016

Front. Pharmacol.

View full text Add to dashboard Cite

Objective: Telavancin is approved to treat complicated skin and skin structure infections, hospital-acquired, and ventilator-associated bacterial pneumonia caused by Staphylococcus aureus. A previous meta-analysis of randomized controlled trials suggested that it might be an alternative to vancomycin in cases of difficult-to-treat meticillin-resistant S. aureus infections. We did a meta-analysis including one new trial to access the efficacy and safety of telavancin.Methods: We searched PubMed, Cochrane Central Register of Controlled Trials, EMBASE and ClinicalTrials.gov up to December 30, 2015 to identify randomized controlled trials that assessed the clinical efficacy, eradication efficiency, adverse events and laboratory abnormalities of telavancin vs. other antibiotic agents for bacterial infection. Meta-analysis was performed using Review Manager 5.3.0.Results: Five studies (3790 participants) were included in the meta-analysis. There was no significant difference in treatment success with telavancin than with control antibiotic agents. The pooled pathogen eradication for the telavancin group was numerically higher than that for the control groups, but there was no significant difference. While all-cause mortalities and serious adverse events were comparable between telavancin and control antibiotic agents, adverse event-related withdrawals (OR 1.47, 95% CI 1.13–1.91) were higher in telavancin group. The total number adverse events were more in the telavancin group than in the control groups, especially in the digestive system (OR 1.57, 95% CI 1.37–1.79), nervous system (OR 2.14, 95% CI 1.86–2.47) and urogenital system (OR 2.54, 95% CI 1.99–3.25). Serum creatinine increase (OR 2.25, 95% Cl 1.78–2.85) and hypokalemia (OR 1.74, 95% CI 1.19–2.53) occurred more frequently in telavancin group compared to control groups.Conclusion: Telavancin may be as effective as but no better than the comparison therapy for S. aureus infection. However, because of the high risk of adverse event-related withdrawals and potential nephrotoxicity, prudence with the clinical use of telavancin in infections is required.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Systematic Review and Meta-Analysis of the Efficacy and Safety of Telavancin for Treatment of Infectious Disease: Are We Clearer?

Chuan

Zhang

et al. 2016

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…While the results of our study were not completely congruent with other lung microbiome studies, the results did seem to correlate with respiratory pathogens. Of the top four hits of the metataxonomic and metagenomic analyses that would be considered part of the human flora or human pathogens rather than environmental pathogens, there were six organisms— N. meningitidis (Van Deuren et al, 2000 ), Corynebacterium pseudodiphtheriticum (Nhan et al, 2012 ), K. pneumoniae (Bratu et al, 2005 ), A. baumannii (Garnacho-Montero et al, 2003 ), P. aeruginosa (de Bentzmann et al, 1996 ; Lister et al, 2009 ), and S. aureus (Hooper and Smith, 2012 ) - that commonly cause respiratory infections. Of these respiratory pathogens, A. baumannii, P. aeruginosa , and S. aureus are commonly associated with VAP (Ashraf and Ostrosky-Zeichner, 2012 ).…”

Section: Resultsmentioning

confidence: 99%

Metataxonomic and Metagenomic Approaches vs. Culture-Based Techniques for Clinical Pathology

et al. 2016

View full text Add to dashboard Cite

Diagnoses that are both timely and accurate are critically important for patients with life-threatening or drug resistant infections. Technological improvements in High-Throughput Sequencing (HTS) have led to its use in pathogen detection and its application in clinical diagnoses of infectious diseases. The present study compares two HTS methods, 16S rRNA marker gene sequencing (metataxonomics) and whole metagenomic shotgun sequencing (metagenomics), in their respective abilities to match the same diagnosis as traditional culture methods (culture inference) for patients with ventilator associated pneumonia (VAP). The metagenomic analysis was able to produce the same diagnosis as culture methods at the species-level for five of the six samples, while the metataxonomic analysis was only able to produce results with the same species-level identification as culture for two of the six samples. These results indicate that metagenomic analyses have the accuracy needed for a clinical diagnostic tool, but full integration in diagnostic protocols is contingent on technological improvements to decrease turnaround time and lower costs.

show abstract

“…The role of S. aureus in hospital-acquired pneumonia, and specifically the fact that over 60% of isolates from US hospitals are resistant to methicillin and therapy is initiated prior to microbiological diagnosis, necessitates the use of antimicrobials with anti-MRSA activity prior to microbiological identification of the causative organism implicated in the pneumonia. [21][22][23][24][25][26] Vancomycin and linezolid are recommended in current guidelines but have limitations, 25,26 while tigecycline is not indicated in ventilator-associated pneumonia and daptomycin is not indicated for hospital-acquired pneumonia. 22,26 Recently, the results of the ATTAIN (Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia) studies were reported.…”

Section: Introductionmentioning

confidence: 99%

“…[21][22][23][24][25][26] Vancomycin and linezolid are recommended in current guidelines but have limitations, 25,26 while tigecycline is not indicated in ventilator-associated pneumonia and daptomycin is not indicated for hospital-acquired pneumonia. 22,26 Recently, the results of the ATTAIN (Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia) studies were reported. 25,28 These studies were international, randomized, double-blind, parallel-group Phase III trials investigating the efficacy and safety of telavancin in the treatment of hospital-acquired pneumonia caused by Gram-positive pathogens in adults.…”

Section: Introductionmentioning

confidence: 99%

Telavancin in the treatment of invasive Gram-positive infections

Rubinstein¹

2012

View full text Add to dashboard Cite

Telavancin is a newer once-daily lipoglycopeptide with activity against Gram-positive bacteria, including those that are resistant to conventional antibiotics like beta-lactams. The results of recent clinical trials led to registration of telavancin for use in skin and skin structure infections in the US and Canada and for nosocomial pneumonia in Europe, based primarily on the favorable results of clinical trials. We review the evidence for use of telavancin in Gram-positive intravascular infections, focusing on bacteremic subpopulations in the large clinical trials as well as anecdotal evidence for use of the drug in the setting of infective endocarditis.

show abstract

Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA)

Cited by 7 publications

References 44 publications

Systematic Review and Meta-Analysis of the Efficacy and Safety of Telavancin for Treatment of Infectious Disease: Are We Clearer?

Systematic Review and Meta-Analysis of the Efficacy and Safety of Telavancin for Treatment of Infectious Disease: Are We Clearer?

Metataxonomic and Metagenomic Approaches vs. Culture-Based Techniques for Clinical Pathology

Telavancin in the treatment of invasive Gram-positive infections

Contact Info

Product

Resources

About